Cowen & Co. analyst Eric Schmidt maintained a Hold rating on Sunesis Pharma (NASDAQ: SNSS) today. The company’s shares opened today at $2.64, close to its 52-week low of $1.82.
According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.8% and a 60.9% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.
Sunesis Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
Based on Sunesis Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.62 million. In comparison, last year the company had a GAAP net loss of $9.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia.
